JP2018523485A - キメラサイトカイン受容体 - Google Patents

キメラサイトカイン受容体 Download PDF

Info

Publication number
JP2018523485A
JP2018523485A JP2018509549A JP2018509549A JP2018523485A JP 2018523485 A JP2018523485 A JP 2018523485A JP 2018509549 A JP2018509549 A JP 2018509549A JP 2018509549 A JP2018509549 A JP 2018509549A JP 2018523485 A JP2018523485 A JP 2018523485A
Authority
JP
Japan
Prior art keywords
ccr
nucleic acid
acid sequence
cytokine receptor
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2018509549A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018523485A5 (https=
Inventor
マーティン プーレ，
マーティン プーレ，
ショーン コルドバ，
ショーン コルドバ，
マッテオ リーギ，
マッテオ リーギ，
ジェイムズ シリボーン，
ジェイムズ シリボーン，
シモビ オヌオハ，
シモビ オヌオハ，
サイモン トーマス，
サイモン トーマス，
Original Assignee
オートラス リミテッド
オートラス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オートラス リミテッド, オートラス リミテッド filed Critical オートラス リミテッド
Publication of JP2018523485A publication Critical patent/JP2018523485A/ja
Priority to JP2019113625A priority Critical patent/JP6979423B2/ja
Publication of JP2018523485A5 publication Critical patent/JP2018523485A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001116—Receptors for cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A61K39/001135—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A61K39/001182—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001194—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4274—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A61K40/4275—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4274—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A61K40/4276—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
JP2018509549A 2015-08-20 2016-08-19 キメラサイトカイン受容体 Withdrawn JP2018523485A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019113625A JP6979423B2 (ja) 2015-08-20 2019-06-19 キメラサイトカイン受容体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1514875.2 2015-08-20
GBGB1514875.2A GB201514875D0 (en) 2015-08-20 2015-08-20 Receptor
PCT/GB2016/052564 WO2017029512A1 (en) 2015-08-20 2016-08-19 Chimeric cytokine receptor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019113625A Division JP6979423B2 (ja) 2015-08-20 2019-06-19 キメラサイトカイン受容体

Publications (2)

Publication Number Publication Date
JP2018523485A true JP2018523485A (ja) 2018-08-23
JP2018523485A5 JP2018523485A5 (https=) 2019-07-25

Family

ID=54292003

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2018509549A Withdrawn JP2018523485A (ja) 2015-08-20 2016-08-19 キメラサイトカイン受容体
JP2019113625A Active JP6979423B2 (ja) 2015-08-20 2019-06-19 キメラサイトカイン受容体
JP2020199336A Active JP7603426B2 (ja) 2015-08-20 2020-12-01 キメラサイトカイン受容体
JP2022178045A Withdrawn JP2022190153A (ja) 2015-08-20 2022-11-07 キメラサイトカイン受容体
JP2025047075A Pending JP2025089404A (ja) 2015-08-20 2025-03-21 キメラサイトカイン受容体
JP2025047074A Pending JP2025089403A (ja) 2015-08-20 2025-03-21 キメラサイトカイン受容体

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2019113625A Active JP6979423B2 (ja) 2015-08-20 2019-06-19 キメラサイトカイン受容体
JP2020199336A Active JP7603426B2 (ja) 2015-08-20 2020-12-01 キメラサイトカイン受容体
JP2022178045A Withdrawn JP2022190153A (ja) 2015-08-20 2022-11-07 キメラサイトカイン受容体
JP2025047075A Pending JP2025089404A (ja) 2015-08-20 2025-03-21 キメラサイトカイン受容体
JP2025047074A Pending JP2025089403A (ja) 2015-08-20 2025-03-21 キメラサイトカイン受容体

Country Status (17)

Country Link
US (6) US10800854B2 (https=)
EP (3) EP4338756A3 (https=)
JP (6) JP2018523485A (https=)
KR (2) KR20240093884A (https=)
CN (2) CN108350047A (https=)
AU (1) AU2016308618B2 (https=)
BR (1) BR112018003308A2 (https=)
CA (2) CA2995785A1 (https=)
CL (2) CL2018000415A1 (https=)
GB (1) GB201514875D0 (https=)
HK (1) HK1252161A1 (https=)
IL (2) IL270207B2 (https=)
MX (2) MX2018002042A (https=)
RU (1) RU2018109350A (https=)
SG (1) SG10201909759UA (https=)
WO (1) WO2017029512A1 (https=)
ZA (1) ZA201904156B (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022522654A (ja) * 2019-03-01 2022-04-20 アロジーン セラピューティクス，インコーポレイテッド Ｐｄ－１外部ドメインを担持するキメラサイトカイン受容体
JP2022524042A (ja) * 2019-03-08 2022-04-27 オートラス リミテッド 操作されたキメラ抗原受容体およびｃａｒの調節因子を含む組成物および方法
JP2024515181A (ja) * 2021-04-19 2024-04-05 ナンジン レジェンド バイオテック カンパニー，リミテッド キメラサイトカイン受容体及びその細胞療法における使用

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4282419A1 (en) 2012-12-20 2023-11-29 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
DK3143134T3 (da) 2014-05-15 2021-01-04 Nat Univ Singapore Modificerede, naturlige dræberceller og anvendelser deraf
GB201514875D0 (en) 2015-08-20 2015-10-07 Autolus Ltd Receptor
GB201518816D0 (en) 2015-10-23 2015-12-09 Autolus Ltd Receptor
EP3439675A4 (en) 2016-04-08 2019-12-18 Purdue Research Foundation METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY
MA46862A (fr) 2016-11-17 2019-09-25 Bluebird Bio Inc Convertisseur de signaux tgf béta
CN110191955B (zh) * 2016-12-13 2024-05-31 西雅图儿童医院（Dba西雅图儿童研究所） 在体外和体内对工程化的细胞中表达的化学物质诱导的信号传导复合物进行外源性药物激活的方法
US11649288B2 (en) 2017-02-07 2023-05-16 Seattle Children's Hospital Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
WO2018160622A1 (en) 2017-02-28 2018-09-07 Endocyte, Inc. Compositions and methods for car t cell therapy
BR112019019917A2 (pt) 2017-03-27 2020-04-22 Nat Univ Singapore receptores quiméricos nkg2d truncados e seus usos em imunoterapia de células exterminadoras naturais
AU2018329741B2 (en) * 2017-09-08 2025-02-20 Poseida Therapeutics, Inc. Compositions and methods for chimeric ligand receptor (CLR)-mediated conditional gene expression
GB201714718D0 (en) * 2017-09-13 2017-10-25 Autolus Ltd Cell
GB201716728D0 (en) 2017-10-12 2017-11-29 Autolus Ltd Cell
GB201717524D0 (en) 2017-10-25 2017-12-06 Autolus Ltd Vectors
GB201719557D0 (en) * 2017-11-24 2018-01-10 Autolus Ltd Polypeptide
CA3084551A1 (en) * 2017-12-14 2019-06-20 Bluebird Bio, Inc. Daric interleukin receptors
US11311576B2 (en) 2018-01-22 2022-04-26 Seattle Children's Hospital Methods of use for CAR T cells
GB201801831D0 (en) * 2018-02-05 2018-03-21 Autolus Ltd Chimeric receptor
US12312416B2 (en) 2018-02-06 2025-05-27 Seattle Children's Hospital Fluorescein-specific cars exhibiting optimal t cell function against FL-PLE labelled tumors
AU2019225174B2 (en) 2018-02-23 2025-11-20 Endocyte, Inc. Sequencing method for CAR T cell therapy
CN111819192A (zh) 2018-03-02 2020-10-23 艾洛基治疗公司 可诱导的嵌合细胞激素受体
JP7334985B2 (ja) 2018-04-02 2023-08-29 ナショナル ユニヴァーシティー オブ シンガポール 免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和
CA3096458A1 (en) 2018-04-12 2019-10-17 Umoja Biopharma, Inc. Viral vectors and packaging cell lines
WO2019210057A1 (en) 2018-04-27 2019-10-31 Seattle Children's Hospital (dba Seattle Children's Research Institute) Rapamycin resistant cells
US11993661B2 (en) * 2018-06-18 2024-05-28 Eureka Therapeutics, Inc. Constructs targeting prostate-specific membrane antigen (PSMA) and uses thereof
CN110615843B (zh) * 2018-06-20 2023-05-09 上海隆耀生物科技有限公司 一种包含第三信号受体的嵌合抗原受体及其应用
GB201812474D0 (en) 2018-07-31 2018-09-12 Autolus Ltd Nucleic acid construct
EP3844186A4 (en) * 2018-08-29 2022-08-17 National University of Singapore METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS
IL281428B2 (en) 2018-09-27 2024-10-01 Autolus Ltd Chimeric antigen receptor
US20200147137A1 (en) * 2018-11-08 2020-05-14 WUGEN, Inc. Compositions and methods for treatment of cancer
CN111378046B (zh) * 2018-12-27 2024-03-15 上海细胞治疗集团有限公司 一种免疫效应细胞转换受体
PE20211902A1 (es) 2019-03-01 2021-09-27 Allogene Therapeutics Inc Receptores de citocinas quimericos constitutivamente activos
EP3773918A4 (en) 2019-03-05 2022-01-05 Nkarta, Inc. CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY
GB201903237D0 (en) 2019-03-08 2019-04-24 Autolus Ltd Method
EP3714941A1 (en) 2019-03-27 2020-09-30 Medigene Immunotherapies GmbH Mage-a4 tcrs
CA3139011A1 (en) 2019-05-08 2020-11-12 Medigene Immunotherapies Gmbh Engineered t cells
GB201911187D0 (en) 2019-08-05 2019-09-18 Autolus Ltd Receptor
US12528856B2 (en) 2019-08-30 2026-01-20 Allogene Therapeutics, Inc. Chimeric cytokine receptors comprising TGF β binding domains
WO2021050752A1 (en) * 2019-09-11 2021-03-18 The Board Of Trustees Of The Leland Stanford Junior University Chimeric orthogonal receptor proteins and methods of use
KR102275668B1 (ko) 2019-09-26 2021-07-12 충북대학교 산학협력단 면역신호의 변환이 가능한 키메릭 사이토카인 수용체, 이를 발현하는 면역세포 및 이의 항암 용도
MX2022004326A (es) * 2019-10-10 2022-07-27 Bryologyx Inc Método para la inducción de antígenos asociados al tumor con briostatina.
CN115210252A (zh) 2020-02-04 2022-10-18 西雅图儿童医院（Dba西雅图儿童研究所） 抗二硝基苯酚的嵌合抗原受体
MX2022010340A (es) 2020-02-24 2022-09-19 Allogene Therapeutics Inc Celulas t con car de bcma con actividades mejoradas.
CN115427440A (zh) * 2020-02-25 2022-12-02 圭尔医疗有限公司 用于工程化细胞的嵌合受体
JP2023520410A (ja) * 2020-03-31 2023-05-17 フレッド ハッチンソン キャンサー センター Ｃｄ３３を標的にするキメラ抗原受容体
CN115348973A (zh) 2020-03-31 2022-11-15 弗莱德哈钦森癌症中心 靶向cd33的嵌合抗原受体
US20230133554A1 (en) 2020-04-09 2023-05-04 Autolus Limited Molecule
GB202101491D0 (en) 2021-02-03 2021-03-17 Autolus Ltd Molecule
GB202007044D0 (en) 2020-05-13 2020-06-24 Autolus Ltd Method
CN113201063B (zh) * 2020-07-31 2022-04-19 北京市神经外科研究所 IL7Rα的截短体及其在制备治疗肿瘤的药物中的用途
WO2022037562A1 (en) * 2020-08-17 2022-02-24 Nanjing Legend Biotech Co., Ltd. Engineered immunoresponsive cells and uses thereof
CN112961248B (zh) * 2021-02-22 2022-03-18 广州百暨基因科技有限公司 共表达IL-7和CCR2b的嵌合抗原受体融合蛋白及其应用
CN113072648B (zh) * 2021-06-04 2021-08-24 诺未科技（北京）有限公司 一种靶向afp的肝癌疫苗
CN113416708A (zh) * 2021-06-10 2021-09-21 深圳市先康达生命科学有限公司 一种表达细胞因子受体融合型嵌合抗原受体的免疫细胞及其应用
US20230086030A1 (en) * 2021-08-30 2023-03-23 Industry-Academic Cooperation Foundation, Yonsei University Lymphoma cell-specific drug delivery system for prevention or treatment of lymphoma and method for preparing same
AU2022348588A1 (en) 2021-09-17 2024-04-04 Parker Institute For Cancer Immunotherapy Switch receptors using il-9 signaling domains
GB202115329D0 (en) 2021-10-25 2021-12-08 Autolus Ltd Chimeric cytokine receptor
JP2025515134A (ja) * 2022-05-04 2025-05-13 アーリ インコーポレイテッド 疾患細胞の位置を決定するおよび／または疾患細胞を処置するために表面発現可能な活性化可能エピトープを使用する方法
CA3259305A1 (en) * 2022-07-11 2024-01-18 Sonoma Biotherapeutics, Inc. RECOMBINANT CYTOKINE RECEPTORS AND METHODS OF USE
JP2025529913A (ja) * 2022-08-26 2025-09-09 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー キメラサイトカイン受容体及び使用方法
CN117402262A (zh) * 2022-10-19 2024-01-16 上海君赛生物科技有限公司 基于lag3的嵌合免疫细胞辅助受体及其用途
WO2024123835A1 (en) * 2022-12-06 2024-06-13 Dynamic Cell Therapies, Inc. Engineered switches for immune cell activity and methods of use thereof
CN120981484A (zh) 2023-01-23 2025-11-18 汉诺威医学院 抗entpd3嵌合抗原受体
EP4403580A1 (en) 2023-01-23 2024-07-24 Medizinische Hochschule Hannover Anti-entpd3 chimeric antigen receptor
AU2024219048A1 (en) 2023-02-07 2025-08-07 Quell Therapeutics Limited Culture method for treg cells
WO2024175805A1 (en) 2023-02-24 2024-08-29 Medizinische Hochschule Hannover Chimeric antigen receptor
EP4420676A1 (en) 2023-02-24 2024-08-28 Medizinische Hochschule Hannover Chimeric antigen receptor
IL322949A (en) 2023-03-03 2025-10-01 Arsenal Biosciences Inc Systems targeting PSMA and CA9
EP4680728A1 (en) 2023-03-17 2026-01-21 Quell Therapeutics Limited Treg therapy
EP4434539A1 (en) 2023-03-20 2024-09-25 Medizinische Hochschule Hannover Chimeric antigen receptor
AU2024240076A1 (en) 2023-03-20 2025-08-28 Autolus Limited A chimeric cytokine receptor, which comprises a truncated il2rbeta and il2rgamma
WO2024194355A1 (en) 2023-03-20 2024-09-26 Medizinische Hochschule Hannover Chimeric antigen receptor
WO2024238287A1 (en) * 2023-05-12 2024-11-21 Chimeris Uk Ltd. Dual blocking and chimeric cytokine receptor
GB202309704D0 (en) 2023-06-27 2023-08-09 Autolus Ltd Chimeric transmembrane protein
GB202312009D0 (en) 2023-08-04 2023-09-20 Autolus Ltd Methods and cell compositions
WO2025189046A2 (en) * 2024-03-06 2025-09-12 The Johns Hopkins University Pantigen specific cytokine receptor stimulation of immune cell function
WO2025221843A1 (en) * 2024-04-17 2025-10-23 Baylor College Of Medicine Methods and compositions for suppressing immune cell activation
WO2026008994A1 (en) 2024-07-04 2026-01-08 Quell Therapeutics Limited Expression construct
GB202411558D0 (en) 2024-08-06 2024-09-18 Quell Therapeutics Ltd Culture method

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010531666A (ja) * 2007-06-26 2010-09-30 ユニバーシティ オブ マイアミ 抗体−エンドスタチン融合タンパク質及びそのバリアント
JP2015513394A (ja) * 2012-02-13 2015-05-14 シアトル チルドレンズ ホスピタル ドゥーイング ビジネ 二重特異性キメラ抗原受容体およびその治療的使用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2164623A1 (en) 1993-06-07 1994-12-22 Robert Enrico Pacifici Hybrid receptor molecules
GB9526131D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Recombinant chimeric receptors
WO1999060120A2 (en) * 1998-05-19 1999-11-25 Avidex Limited Soluble t cell receptor
EP1399472B1 (en) * 2001-03-09 2009-06-03 ZymoGenetics, Inc. Soluble heterodimeric cytokine receptor
CN1659274A (zh) * 2002-04-19 2005-08-24 津莫吉尼蒂克斯公司 细胞因子受体
JP2004113062A (ja) 2002-09-25 2004-04-15 Teruyuki Nagamune キメラ受容体を有する動物細胞とその利用
CN101027079B (zh) * 2004-10-12 2011-08-17 美国蛋白质公司 嵌合蛋白
WO2007115230A2 (en) 2006-03-30 2007-10-11 University Of Medicine And Dentistry Of New Jersey A strategy for homo- or hetero-dimerization of various proteins in solutions and in cells
WO2008045437A2 (en) * 2006-10-09 2008-04-17 The General Hospital Corporation Chimeric t-cell receptors and t-cells targeting egfrviii on tumors
WO2010085660A2 (en) * 2009-01-23 2010-07-29 Roger Williams Hospital Viral vectors encoding multiple highly homologous non-viral polypeptides and the use of same
EP2478110B1 (en) 2009-09-16 2016-01-06 Immunomedics, Inc. Class i anti-cea antibodies and uses thereof
CA2832569A1 (en) 2011-04-08 2012-10-11 Baylor College Of Medicine Reversing the effects of the tumor microenvironment using chimeric cytokine receptors
RU2522004C2 (ru) 2012-04-10 2014-07-10 Владимир Константинович Боженко Одноцепочечное антитело к раково-эмбриональному антигену, химерный мономолекулярный т-клеточный рецептор, вектор и клетка-хозяин для обеспечения экспрессии такого рецептора и способ диагностики или лечения.
US20130280220A1 (en) 2012-04-20 2013-10-24 Nabil Ahmed Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes
GB201405845D0 (en) * 2014-04-01 2014-05-14 Ucl Business Plc Signalling system
MA41538A (fr) * 2014-10-17 2017-12-26 Baylor College Medicine Cellules immunitaires bipartites et tripartites de signalisation
GB201514875D0 (en) 2015-08-20 2015-10-07 Autolus Ltd Receptor
GB201518816D0 (en) 2015-10-23 2015-12-09 Autolus Ltd Receptor
GB201518817D0 (en) 2015-10-23 2015-12-09 Autolus Ltd Cell
GB201719557D0 (en) 2017-11-24 2018-01-10 Autolus Ltd Polypeptide
IL281428B2 (en) 2018-09-27 2024-10-01 Autolus Ltd Chimeric antigen receptor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010531666A (ja) * 2007-06-26 2010-09-30 ユニバーシティ オブ マイアミ 抗体−エンドスタチン融合タンパク質及びそのバリアント
JP2015513394A (ja) * 2012-02-13 2015-05-14 シアトル チルドレンズ ホスピタル ドゥーイング ビジネ 二重特異性キメラ抗原受容体およびその治療的使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF IMMUNOLOGICAL METHODS, vol. VOL:337, NR:1, JPN5018004978, 10 June 2008 (2008-06-10), NL, pages 16 - 23, ISSN: 0004429523 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022522654A (ja) * 2019-03-01 2022-04-20 アロジーン セラピューティクス，インコーポレイテッド Ｐｄ－１外部ドメインを担持するキメラサイトカイン受容体
JP7633937B2 (ja) 2019-03-01 2025-02-20 アロジーン セラピューティクス，インコーポレイテッド Ｐｄ－１外部ドメインを担持するキメラサイトカイン受容体
JP2022524042A (ja) * 2019-03-08 2022-04-27 オートラス リミテッド 操作されたキメラ抗原受容体およびｃａｒの調節因子を含む組成物および方法
JP7602475B2 (ja) 2019-03-08 2024-12-18 オートラス リミテッド 操作されたキメラ抗原受容体およびｃａｒの調節因子を含む組成物および方法
JP2024515181A (ja) * 2021-04-19 2024-04-05 ナンジン レジェンド バイオテック カンパニー，リミテッド キメラサイトカイン受容体及びその細胞療法における使用

Also Published As

Publication number Publication date
MX421045B (es) 2025-02-10
ZA201904156B (en) 2025-09-25
JP2021035395A (ja) 2021-03-04
CN108350047A (zh) 2018-07-31
IL257234A (en) 2018-03-29
IL270207A (https=) 2019-12-31
CN110724200A (zh) 2020-01-24
US20210040228A1 (en) 2021-02-11
JP2025089404A (ja) 2025-06-12
US20180244797A1 (en) 2018-08-30
KR20180054625A (ko) 2018-05-24
RU2018109350A (ru) 2019-09-23
MX2018002042A (es) 2018-06-19
IL270207B2 (en) 2024-06-01
US20230133682A1 (en) 2023-05-04
AU2016308618B2 (en) 2021-05-13
SG10201909759UA (en) 2019-11-28
BR112018003308A2 (pt) 2018-09-18
CL2019001107A1 (es) 2019-07-05
US20190016820A1 (en) 2019-01-17
CA3091907C (en) 2023-10-31
GB201514875D0 (en) 2015-10-07
JP7603426B2 (ja) 2024-12-20
MX2019013204A (es) 2020-01-21
KR102669749B1 (ko) 2024-05-28
JP2019150066A (ja) 2019-09-12
NZ739942A (en) 2022-03-25
US10800854B2 (en) 2020-10-13
US20250333538A1 (en) 2025-10-30
JP6979423B2 (ja) 2021-12-15
EP3337814A1 (en) 2018-06-27
AU2016308618A1 (en) 2018-03-08
CN110724200B (zh) 2024-01-26
IL270207B1 (en) 2024-02-01
EP3438123A1 (en) 2019-02-06
US10800855B2 (en) 2020-10-13
HK1252161A1 (zh) 2019-05-17
KR20240093884A (ko) 2024-06-24
US11479614B2 (en) 2022-10-25
JP2025089403A (ja) 2025-06-12
US11479613B2 (en) 2022-10-25
US12234295B2 (en) 2025-02-25
RU2018109350A3 (https=) 2019-12-09
US20210040227A1 (en) 2021-02-11
EP4338756A2 (en) 2024-03-20
EP4338756A3 (en) 2024-06-05
CA2995785A1 (en) 2017-02-23
CA3091907A1 (en) 2017-02-23
CL2018000415A1 (es) 2018-07-20
JP2022190153A (ja) 2022-12-22
WO2017029512A1 (en) 2017-02-23

Similar Documents

Publication Publication Date Title
JP7603426B2 (ja) キメラサイトカイン受容体
US20220289820A1 (en) Chimeric cytokine receptor
JP2018532407A (ja) 受容体
JP2024539281A (ja) キメラサイトカイン受容体
RU2826122C1 (ru) Химерный цитокиновый рецептор
HK1261141A1 (en) Chimeric cytokine receptor
CN120917054A (zh) 嵌合细胞因子受体，其包含截短的IL2Rβ和IL2Rγ
HK40104079A (en) Chimeric cytokine receptor
NZ739942B2 (en) Chimeric cytokine receptor
BR122019010114B1 (pt) Proteína transmembranar quimérica, método para fazer uma célula compreendendo uma proteína transmembranar quimérica, composição farmacêutica e uso de uma composição farmacêutica

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190619

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190619

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200601

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200820

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210121

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20210311